[Late reversal leprous reaction appearing 18 months after the termination of treatment].
P
P
Bourée
A
A
de Brette
G Y
GY
de Carsalade
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D002991:Clofazimine / Q000008:administration & dosage / Q000627:therapeutic use; D004396:Coloring Agents; D005500:Follow-Up Studies; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology*; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D015439:Leprosy, Borderline / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000187:drug effects / Q000276:immunology*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004396:Coloring Agents; D007917:Leprostatic Agents; D002991:Clofazimine; D011241:Prednisone